Trial · NCT02937116
Participant flow36
How many started, completed or left each group, period by period.
1 to 20 of 36
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | 3 | |
| Overall Study | STARTED | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | 3 | |
| Overall Study | STARTED | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | 3 | |
| Overall Study | STARTED | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | 3 | |
| Overall Study | STARTED | MEL: Sintilimab 200mg Q3W (Cohort A) | 22 | |
| Overall Study | STARTED | Malignant Tumor of the Digestive System or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | 87 | |
| Overall Study | STARTED | NSCLC: Sintilimab 200mg Q3W (Cohort C) | 37 | |
| Overall Study | STARTED | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | 21 | |
| Overall Study | STARTED | scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E) | 20 | |
| Overall Study | STARTED | Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F) | 20 | |
| Overall Study | STARTED | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G) | 7 | |
| Overall Study | STARTED | Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H) | 7 | |
| Overall Study | COMPLETED | Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1) | 0 | |
| Overall Study | COMPLETED | Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2) | 0 | |
| Overall Study | COMPLETED | Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3) | 0 | |
| Overall Study | COMPLETED | Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4) | 0 | |
| Overall Study | COMPLETED | MEL: Sintilimab 200mg Q3W (Cohort A) | 0 | |
| Overall Study | COMPLETED | Malignant Tumor of the Digestive System or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B) | 0 | |
| Overall Study | COMPLETED | NSCLC: Sintilimab 200mg Q3W (Cohort C) | 0 | |
| Overall Study | COMPLETED | nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D) | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02937116/flow